Supernus Pharmaceuticals Inc
SUPN36.329USD
+0.824+2.32%
Market hours （ET）Quotes delayed by 15 min
2.03BMarket Cap
32.85P/E TTM
More Details of Supernus Pharmaceuticals Inc Company
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Company Info
Ticker SymbolSUPN
Company nameSupernus Pharmaceuticals Inc
IPO dateDec 28, 2010
CEOMr. Jack A. Khattar
Number of employees674
Security typeOrdinary Share
Fiscal year-endDec 28
Address9715 Key West Avenue
CityROCKVILLE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code20850
Phone13018382500
Websitehttps://www.supernus.com
Ticker SymbolSUPN
IPO dateDec 28, 2010
CEOMr. Jack A. Khattar
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.01M
--
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
53.76K
--
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
15.15K
+4.64%
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
12.70K
+7.63%
Mr. Timothy C. (Tim) Dec, CPA
Mr. Timothy C. (Tim) Dec, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
12.68K
+7.65%
Dr. Jonathan Rubin, M.D.
Dr. Jonathan Rubin, M.D.
Senior Vice President, Chief Medical Officer - Research and Development
Senior Vice President, Chief Medical Officer - Research and Development
9.63K
+8.32%
Mr. Charles W. Newhall, III
Mr. Charles W. Newhall, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bethany L. Sensenig
Ms. Bethany L. Sensenig
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.01M
--
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
53.76K
--
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
15.15K
+4.64%
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
12.70K
+7.63%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Net product sales-Qelbree
64.75M
43.21%
Net product sales - GOCOVRI
30.69M
20.48%
Net product sales-APOKYN
14.98M
10.00%
Net product sales- Trokendi XR
12.80M
8.54%
Net product sales- Oxtellar XR
10.20M
6.81%
Other
16.41M
10.96%
By RegionUSD
Name
Revenue
Proportion
United States
149.82M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Net product sales-Qelbree
64.75M
43.21%
Net product sales - GOCOVRI
30.69M
20.48%
Net product sales-APOKYN
14.98M
10.00%
Net product sales- Trokendi XR
12.80M
8.54%
Net product sales- Oxtellar XR
10.20M
6.81%
Other
16.41M
10.96%
Shareholding Stats
Updated: Thu, May 8
Updated: Thu, May 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.65%
The Vanguard Group, Inc.
10.99%
Armistice Capital LLC
9.28%
Dimensional Fund Advisors, L.P.
5.19%
Macquarie Investment Management
4.82%
Other
55.07%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.65%
The Vanguard Group, Inc.
10.99%
Armistice Capital LLC
9.28%
Dimensional Fund Advisors, L.P.
5.19%
Macquarie Investment Management
4.82%
Other
55.07%
Shareholder Types
Shareholders
Proportion
Investment Advisor
56.83%
Investment Advisor/Hedge Fund
30.46%
Hedge Fund
15.36%
Individual Investor
4.11%
Research Firm
2.96%
Pension Fund
1.70%
Venture Capital
0.93%
Bank and Trust
0.70%
Sovereign Wealth Fund
0.27%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
563
63.74M
113.85%
-2.63M
2025Q1
587
64.77M
115.71%
-2.86M
2024Q4
569
65.17M
116.92%
-2.59M
2024Q3
551
65.02M
117.72%
-2.14M
2024Q2
536
63.49M
115.33%
-2.27M
2024Q1
535
61.47M
111.83%
-3.83M
2023Q4
534
61.60M
112.54%
-3.30M
2023Q3
534
60.88M
111.42%
-4.46M
2023Q2
534
61.11M
111.93%
-1.60M
2023Q1
539
59.34M
108.94%
-3.56M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
8.20M
14.65%
-297.23K
-3.50%
Mar 31, 2025
The Vanguard Group, Inc.
6.15M
10.99%
+13.13K
+0.21%
Mar 31, 2025
Armistice Capital LLC
5.20M
9.28%
+360.00K
+7.44%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.90M
5.19%
+25.18K
+0.87%
Mar 31, 2025
Macquarie Investment Management
2.70M
4.82%
+70.76K
+2.69%
Mar 31, 2025
State Street Global Advisors (US)
2.15M
3.83%
-42.85K
-1.96%
Mar 31, 2025
Khattar (Jack A)
2.01M
3.6%
--
--
Apr 22, 2025
Renaissance Technologies LLC
1.59M
2.83%
-13.00K
-0.81%
Mar 31, 2025
Stephens Investment Management Group, LLC
1.74M
3.1%
-13.59K
-0.78%
Mar 31, 2025
Loomis, Sayles & Company, L.P.
1.44M
2.57%
-26.38K
-1.80%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Neuroscience and Healthcare ETF
4.1%
Invesco Pharmaceuticals ETF
2.62%
SPDR S&P Pharmaceuticals ETF
2.05%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.45%
Invesco S&P SmallCap Health Care ETF
1.26%
Lattice Hartford Multifactor Small Cap ETF
0.93%
iShares U.S. Pharmaceuticals ETF
0.89%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.65%
VictoryShares Small Cap Free Cash Flow ETF
0.47%
Distillate Small/Mid Cash Flow ETF
0.47%
View more
iShares Neuroscience and Healthcare ETF
Proportion4.1%
Invesco Pharmaceuticals ETF
Proportion2.62%
SPDR S&P Pharmaceuticals ETF
Proportion2.05%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.45%
Invesco S&P SmallCap Health Care ETF
Proportion1.26%
Lattice Hartford Multifactor Small Cap ETF
Proportion0.93%
iShares U.S. Pharmaceuticals ETF
Proportion0.89%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion0.65%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.47%
Distillate Small/Mid Cash Flow ETF
Proportion0.47%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
